Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases by Gadola, Stephan D. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $8.00
Vol. 203, No. 10,  October 2, 2006  2293–2303  www.jem.org/cgi/doi/10.1084/jem.20060921
2293
Presentation of glycosphingolipid (GSL) anti-
gens via highly conserved, β2-microglobulin–
associated CD1d molecules has recently been 
shown to exert important regulatory immune 
functions in mouse and man (1, 2). These ef-
fects are mediated by invariant natural killer 
T cells (iNKT cells), a highly specialized subset 
of CD1d-restricted T lymphocytes that are 
characterized by their use of an invariant TCR 
α chain and expression of markers specifi  c for 
NK cells (3).
Human and mouse CD1d molecules can 
bind a diverse range of endogenous lipid 
  ligands, including GSLs (4). An endogenous 
globoside, isoglobotrihexosylceramide (iGb3), 
has recently been shown to activate both 
  human and mouse iNKT cells (5, 6). Synthetic 
α-galactosylceramide (α-GalCer), originally 
isolated from a marine sponge, is widely used 
for in vitro and in vivo experiments of iNKT 
cell function for its ability to stimulate iNKT 
cells in a CD1d- and TCR-dependent manner. 
Studies in germ-free mice, CD1d-defi  cient 
mice (CD1d−/−), and with human cord blood 
indicate that iNKT cells are positively selected 
via endogenous antigens (7, 8). For presenta-
tion to iNKT cells, these antigens are loaded in 
an apparently saposin-dependent process onto 
CD1d molecules within the late endosome/
lysosome (9, 10).
Late endocytic and lysosomal compart-
ments are the major intracellular sites of enzy-
matic GSL degradation. Inherited defi  ciencies 
of lysosomal hydrolases or one of their cofactors 
give rise to human sphingolipid storage diseases, 
which are characterized by the intracellular 
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Reduced numbers of iNKT cells resulted in the absence of cytokine production in response 
to 𝗂-galactosylceramide (𝗂-GalCer) and reduced iNKT cell–mediated lysis of wild-type 
targets loaded with 𝗂-GalCer. The reduction in iNKT cells did not result from defective ex-
pression of CD1d or a lack of antigen-presenting cells. Although H-2 restricted CD4+ T cell 
responses were generally unaffected, processing of a lysosome-dependent analogue of 
𝗂-GalCer was impaired in all the strains of mice tested. These data suggest that GSL stor-
age may result in alterations in thymic selection of iNKT cells caused by impaired presenta-
tion of selecting ligands.
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  accumulation of storage lipids within lysosomes (11, 12). We 
reasoned that loading of endogenous iNKT cell ligands onto 
CD1d within late endocytic compartments could be defec-
tive in lysosomal GSL storage disease. This could arise as a 
result of the entrapment of endogenous ligands within 
membranous cytoplasmic storage bodies or as a result of 
these ligands being out-competed by storage lipids for 
binding to CD1d. To test this hypothesis, we have studied 
the frequency, function, and selection of iNKT cells in 
multiple independent mouse models of GSL storage. These 
include the GM1 gangliosidosis model (defi  cient  in 
β-  galactosidase) and a Niemann-Pick disease type C1 
(NPC1) model. NPC1 does not result from mutations in a 
lysosomal enzyme or cofactor but from defects in the NPC1 
transmembrane protein of the late endosome/lysosome, 
which is currently of unknown function. In NPC1, there is 
a block in the egress of cholesterol and some sphingolipids 
from the late endosome (13). These diseases, therefore, 
have radically diff   erent etiologies and display disease-
  specifi  c patterns of GSL storage (14). In this paper we show 
that iNKT cells are defi  cient in GSL storage models irre-
spective of the disease-specifi   c defect, and we discuss 
  potential mechanisms.
RESULTS
Defi  ciency of iNKT cells in diverse mouse models of GSL 
storage disease
Selection of iNKT cells occurs through interaction with 
CD1d molecules presenting endogenous GSLs (15). The ab-
errant accumulation of GSLs in the lysosome in storage dis-
eases therefore has the potential to negatively aff  ect  this 
process. We have investigated several GSL storage disease 
models that diff  er in terms of their primary etiology and store 
GSLs from diff  erent branches of the GSL catabolic pathway 
(Table I) (14).
We determined the percentage of iNKT cells in the 
  thymus, spleen, and liver of diff  erent GSL storage mice and 
controls using CD1d tetramers loaded with the synthetic 
iNKT cell ligand α-GalCer. The organ-specifi  c fl  ow cytom-
etry data are summarized for all models tested in Fig. 1 and 
Fig. S1 (available at http://jem.org/cgi/content/full/jem.
20060921/DC1). In the mouse models of Sandhoff  , GM1 
gangliosidosis, Fabry, late-onset Tay-Sachs disease (LOTS), 
and NPC1, there was a signifi  cant reduction in the percent-
age of iNKT cells across all organs tested (ranging from a 
50 to 90% reduction, depending on the model and organ; 
Fig. 1). Tay-Sachs mice showed a reduction in liver but not 
in the spleen or thymus. This mouse model has low levels of 
GM2 and GA2 storage relative to the other models and a 
normal life expectancy (Table I). We confi  rmed these results 
by examining iNKT cells as a percentage of total lympho-
cytes and the total cell number from the spleen and thymus 
from Sandhoff  , GM1 gangliosidosis, NPC1, and Fabry mice. 
These data show a reduction in the iNKT cells as both a per-
centage of total lymphocytes and as absolute numbers in each 
model tested (Fig. S1). In contrast, the NPC1+/+ thymic 
iNKT cell population was larger than that of other control 
animals. The percentage of iNKT cells detected in the liver 
of NPC1 control mice (NPC1+/+), which are on a BALB/c 
background, was reduced relative to the controls of the other 
models that are on a C57BL/6 background. However, there 
Figure 1.  The percentage of iNKT cells is reduced in the majority 
of mouse models of GSL storage disease tested. Splenocytes, thymo-
cytes, and purifi  ed liver lymphocytes from homozygous Sandhoff, NPC1, 
Fabry, Tay-Sachs, LOTS, and GM1 gangliosidosis mice were analyzed by 
fl  ow cytometry for the presence of iNKT cells. Cells were stained with CD3 
and α-GalCer/CD1d tetramer. The percentage of CD3+/tetramer+ cells 
(mean ± SE; n = 4–8 animals/group) from homozygous GSL storage dis-
ease animals were compared with those from control animals. Statistical 
signifi  cance between GSL storage disease and controls (using the t test) is 
indicated. *, P ≤ 0.05. NT, not tested.
Table I. Mouse models of human GSL storage disease
Disease Lifespan Defect Major storage GSLs
Tay-Sachs  2  yr β-hexosaminidase A Minor storage of GM2 and GA2
aLOTS  2  yr β-hexosaminidase A GM2 and GA2
Sandhoff  4–5  mo β-hexosaminidase A/B GM2, GA2, and globoside
Fabry  2  yr α-galactosidase A Gb3
GM1 gangliosidosis   7–9 mo β-galactosidase GM1 and GA1
bNPC1   2.5 mo NPC1 protein GM2, GM3, GlcCer, and LacCer
aLOTS mice become symptomatic at 6–12 mo but live to 2 yr (reference 32). The Tay-Sachs mice typically remain healthy until 2 yr.
bNPC1 is a transmembrane protein of the late endosome/lysosome, not a catabolic enzyme, in contrast with the enzyme defi  ciencies that characterize the other diseases.JEM VOL. 203, October 2, 2006  2295
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was no diff  erence in terms of absolute iNKT cell numbers 
relative to control strains (Fig. S1). Additionally, a bias to-
ward a CD4+ phenotype was observed in intrasplenic 
iNKT cells of the genetically identical Tay-Sachs and LOTS 
mice but not in the genetic background control mice 
  (unpublished data).
Functional responses to 𝗂-GalCer are abrogated in GSL 
storage mice, whereas CD1d levels are generally unaffected
To determine whether the in vivo function of iNKT cells is 
diminished in GSL storage mice, we examined the iNKT-
dependent response to injection of α-GalCer. Injection of 
α-GalCer in mice rapidly induces secretion of several diff  erent 
cytokines, including IL-4 and IFN-γ, into the serum (16). 
Although both IL-4 and IFN-γ showed normal profi  les in 
control mice treated with α-GalCer, Sandhoff   and NPC1 
mice (as well as Fabry mice; unpublished data) failed to pro-
duce detectable levels of either cytokine (Fig. 2). Further-
more, in vivo cytotoxicity assays (17) demonstrated that the 
elimination of α-GalCer–pulsed and C20:2 analogue–pulsed 
wild-type targets by iNKT cells were severely reduced in the 
Sandhoff   homozygote compared with control recipients (Fig. 
3, B and C). These data are consistent with the low frequency 
of iNKT cells detected in these mouse models and indicate 
that residual iNKT cells are capable of antigen-specifi  c lysis 
in vivo. Owing to surface loading of C20:2 onto CD1d (18), 
this ligand is effi   ciently presented by splenocytes, which re-
sults in an increase in killing effi   ciency observed in both wild-
type and Sandhoff   mice. Consistent with these observations, 
we demonstrated that residual iNKT cells from Sandhoff    
and GM1 gangliosidosis mice were capable of releasing 
IFN-γ in ELISPOT assays when stimulated by α-GalCer–
pulsed bone marrow–derived DCs (BMDCs) from wild-type 
mice (Fig. S2, available at http://jem.org/cgi/content/full/
jem.20060921/DC1). These data were confi  rmed by ELISA 
(unpublished data). Given these data, it is unlikely that the 
Figure 2.  Cytokine release in response to injection of 𝗂-GalCer is 
completely abrogated in GSL storage disease mice. Homozygous 
Sandhoff and NPC1, wild-type, and CD1d−/− control mice were injected 
i.v with 1 μg α-GalCer or vehicle. Blood samples were taken at 0, 2, 6 and 
24 h, and the serum was analyzed by capture ELISA for the presence of 
IFN-γ (A) and IL-4 (B). The data represent the mean ± SE (n = 3–4 
mice/group).
Figure 3.  In vivo killing of 𝗂-GalCer–pulsed targets is reduced in 
GSL storage disease mice. (A) Schematic representation of the experi-
ment. Splenocytes from wild-type donors were pulsed with α-GalCer or 
the C20:2 analogue and labeled with CFSE. Vehicle-pulsed targets 
(CMTMR labeled) were used in each case as internal controls. Target cells 
were injected i.v. into iNKT−/−, wild-type, or Sandhoff homozygote recipi-
ents, and specifi  c lysis was measured by fl  ow cytometry after 48 h. Target 
cells were pulsed with 0.05 (black shaded), 0.5 (open), or 5 (gray shaded) 
μg/ml α-GalCer or C20:2 analogue. Splenocytes from wild-type donors 
were pulsed with α-GalCer (B) or the C20:2 analogue (C). The data repre-
sent the mean percent specifi  c lysis (±SE; n = 3–5 mice/group) and were 
calculated by the formula described in Materials and methods.2296  REDUCTION OF INKT CELLS IN GLYCOSPHINGOLIPIDOSES | Gadola et al.
residual iNKT cells have an inherent functional defect, but 
additional experiments need to be done to address this ques-
tion more completely.
To further investigate the possible reasons for the reduced 
iNKT cell frequencies in GSL storage mice, we measured the 
cell surface CD1d expression on thymocytes and splenic B 
cells in GSL storage models and age-matched controls. Cell 
surface expression of CD1d molecules, particularly in the 
thymus, was not substantially altered in storage disease mice 
(Fig. 4, A and B; and not depicted). The only exceptions 
were a 40% reduction in the thymus and a 20% reduction in 
the spleen of NPC1 mice, and a small increase in the thymus 
in Fabry mice (Fig. 4, A and B).
To determine whether storage disease mice had a gen-
eralized defect in APC numbers that could contribute to 
the iNKT cell defi  ciency, we analyzed B cell (unpublished 
data), macrophage, and DC frequencies in these animals 
(Table II). There was a small increase in the splenic macrophage 
Figure 4.  Cell surface expression of CD1d in GSL storage disease 
mice is unaffected, with the exception of NPC1 mice. Cell surface 
expression of CD1d on the surface of thymocytes and peripheral B cells 
(gating on CD19+ CD1dint splenocytes) from Sandhoff, NPC1, GM1 gan-
gliosidosis, Fabry, and control mice was assessed by fl  ow cytometry. 
(A) Relative percentage expression (compared with controls) of CD1d cell 
surface level (mean ± SE; n = 3–5 mice/group) comparing homozygous and 
control mice. (B) Representative histogram overlays showing the level of 
CD1d expression on CD1d−/− (dotted line histogram), homozygote (dashed 
line histogram), and wild-type control (fi  lled gray histogram) thymocytes.
Table II. Percentages of APCs within different disease models
Spleen Thymus Liver
Macrophage DC Macrophage DC Macrophage DC
C57BL/6 8.2 ± 0.5 2.5 ± 0.1 0.71 ± 0.04 0.51 ± 0.03 11.6 ± 1.9 3.1 ± 0.4
Sandhoff a11.3 ± 0.8 a1.6 ± 0.2 0.74 ± 0.1 0.6 ± 0.02 8.7 ± 1 3.6 ± 0.5
Tay-Sachs 9.2 ± 1.2 a1.7 ± 0.1 0.66 ± 0.03 a0.64 ± 0.03 8.1 ± 0.8 a1.5 ± 0.4
GM1 gangliosidosis a10.2 ± 0.4 a1.9 ± 0.1 0.95 ± 0.1 0.61 ± 0.05 9.7 ± 1 2.8 ± 0.4
Fabry a10.5 ± 0.6 2.3 ± 1.1 a0.54 ± 0.02 0.61 ± 0.05 14 ± 2.7 3.8 ± 0.5
NPC1+/+ 4.9 ± 0.2 1.01 ± 0.02 0.44 ± 0.02 0.61 ± 0.02 12.5 ± 2.02 1.8 ± 0.2
NPC1 a4 ± 0.1 1.17 ± 0.07 a0.55 ± 0.02 a1.1 ± 0.13 9.22 ± 0.24 a3.26 ± 0.005
Cell suspensions from the various tissues were stained with antibodies against CD11c and CD68 to detect DCs and macrophages, respectively.
aStatistical signifi  cance between GSL storage disease and controls using the t test (P ≤ 0.05).JEM VOL. 203, October 2, 2006  2297
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population in Sandhoff  , GM1 gangliosidosis, and Fabry mice, 
whereas the DCs were slightly reduced in Sandhoff   and GM1 
gangliosidosis mice. In the thymus, there were only subtle 
diff  erences in APC frequencies between GSL storage models 
and controls (Table II). The percentage of cortical thymo-
cytes was generally unaff  ected in younger Sandhoff  , GM1 
gangliosidosis, and NPC1 mice, whereas a loss in iNKT cells 
in both Sandhoff   and NPC1 mice was already observed at 
this age (unpublished data).  Therefore, we conclude that the 
defi  ciency of iNKT cells in lysosomal GSL storage diseases is 
not caused by defective CD1d expression in either the thy-
mus or periphery or a lack of CD1d+ APCs.
Peptide antigen processing and presentation by MHC 
class II molecules are not affected by GSL storage
Processing and presentation of peptides onto MHC class II 
molecules is dependent on functional late endosomes/lyso-
somes (19). Therefore, lipid storage has the potential to dis-
rupt these processes. We tested the capacity of Sandhoff   mice 
to generate functional CD4+ T cell responses to a model an-
tigen, OVA. The CD4+ T cell responses against two diff  er-
ent I-Ab–binding OVA peptides, OVA265-280 (Fig. 5 A) and 
OVA323-339 (not depicted), were measured in an IFN-γ 
ELISPOT assay in Sandhoff   and control mice. Mice were 
  either 6 wk (before onset of neurological signs) or 10 wk of 
age (when the animals have a neurodegenerative phenotype). 
Strong OVA-specifi  c responses of similar magnitude in Sand-
hoff   mice (6 and 10 wk of age) and age-matched controls 
were detected after prime-boost immunization with OVA. 
These data rule out any impairment of OVA processing and 
presentation via MHC class II molecules. Although both 
Fabry (Fig. 5 B) (20) and GM1 gangliosidosis mice made class 
II–restricted responses, NPC1 mice had a reduced ability to 
generate anti-OVA responses (not depicted). Furthermore, 
the proportion of thymic CD4+ T cells in Sandhoff   and con-
trol mice were similar, which was consistent with unimpaired 
H-2–dependent thymic selection (unpublished data).
GSL storage affects positive selection of iNKT cells
Diff  erent maturation stages of iNKT cells have recently been 
defi  ned in mice (21–23). After positive selection (24), α-
  GalCer/CD1d–specifi   c thymocytes bearing the invariant 
TCR α chain (TCR Vα14-Jα18) sequentially express CD44 
and NK1.1 molecules, respectively. To investigate whether 
GSL storage aff  ects thymic development of iNKT cells, we 
analyzed the populations of iNKT cells at diff  erent stages of 
Figure 5.  CD4+ T cell responses are unaffected in GSL storage 
disease mice. (A) Sandhoff mice and controls (6 and 10 wk old) and 
(B) Fabry mice were primed with CFA/OVA s.c. and boosted with UV-
  inactivated vaccinia virus encoding full-length OVA i.v. 1 wk after boosting, 
splenocytes were isolated, and an overnight IFN-γ ELISPOT assay was 
performed using the I-Ab binding peptide OVA265-280. Data represent the 
mean ± SE of the number of IFN-γ–producing spots per 106 cells from 
naive controls and prime-boosted mice (n = 3–5 mice/group).
Figure 6.  Selection and maturation of iNKT cells is compromised 
in the thymus of Sandhoff and GM1 gangliosidosis mice. Four-color 
fl  ow cytometry was performed on thymocytes from Sandhoff, GM1 gan-
gliosidosis, and age-matched control mice. Cells were stained with NK1.1 
and CD44 antibodies, a pan–TCR Vβ antibody, and an α-GalCer/CD1d 
tetramer. The maturation phenotype was analyzed by gating on CD3+/
tetramer+ cells. (A) The percentage of thymic iNKT cells of the immature 
CD44−/NK1.1−, semimature CD44+/NK1.1−, or mature CD44+/NK1.1+ phe-
notype as a percentage of α-GalCer/CD1d tetramer+/Vβ+ cells. (B) Total 
number of iNKT cells at three different stages of maturation (CD44−/
NK1.1−, CD44+/NK1.1−, and CD44+/NK1.1+) from homozygous Sandhoff 
or GM1 gangliosidosis mice and controls are shown. Data represent one 
of two independent experiments (mean ± SE; n = 3–5 mice/group).2298  REDUCTION OF INKT CELLS IN GLYCOSPHINGOLIPIDOSES | Gadola et al.
thymic maturation in Sandhoff   and GM1 gangliosidosis mice 
and controls (Fig. 6 A). The diff  erent iNKT cell populations 
observed in age-matched control mice were similar to 
  previous reported data (25). The majority of thymic iNKT 
cells were of the “mature” CD44+/NK1.1+ phenotype, with 
  subpopulations of the “semimature”  CD44+/NK1.1− and 
“  immature” CD44−/NK1.1− cells. All three maturation 
stages could be clearly identifi  ed in both strains of mice 
  (percent of gated tetramer+/TCR+ cells; Fig. 6 A). How-
ever, both Sandhoff   and GM1 gangliosidosis mice exhibited 
a striking reduction in absolute numbers of α-GalCer/CD1d–
  specifi  c thymocytes at all three stages of development studied 
(Fig. 6 B), culminating in the most signifi  cant reduction at the 
mature CD44+/NK1.1+ stage. These results are consistent 
with   impaired thymic-positive selection of iNKT cells caused 
by GSL storage.
To further analyze whether thymocytes, necessary for 
the positive selection of iNKT cells (15), display inappro-
priate GSL accumulation in Sandhoff   mice, we performed 
quantitative analysis of the levels of GSL storage in total 
thymus. As shown in Table III, the levels of GM2 and GA2 
were signifi  cantly elevated in 10–12-d-old Sandhoff   thy-
mus compared with age-matched controls, whereas the 
level of GM3 was reduced. As expected, the levels of GM1a, 
GM1b, and GA1, not substrates for β-hexosaminidase A/B, 
were unchanged.
It is known that macrophages accumulate considerable 
levels of GSLs within late endosomes/lysosomes in Sandhoff   
disease (unpublished data). Therefore, it was possible that the 
storage of GSLs observed in the thymus (Table III) was caused 
by resident macrophages and not thymocytes. To determine 
whether GSLs are also stored in thymocytes, we examined 
the size/number of lysosomes in thymocytes using Lyso-
Tracker staining. (Table III). We found that the relative fl  uo-
rescence intensity of staining was signifi   cantly elevated in 
Sandhoff   thymocytes compared with wild-type controls. An 
increase in the number and/or size of lysosomes within these 
cells suggests that thymocytes are storing GSLs. Collectively, 
these data suggest that accumulation of GSLs within late 
  endosomes/lysosomes in thymocytes may impair selection of 
iNKT cells in Sandhoff   mice.
Impaired presentation of exogenous ligands by GSL 
storage APCs
To further examine the mechanism for the loss of iNKT cells 
in the diff  erent GSL storage disease mice, we performed ex-
periments using α-GalCer and an analogue that requires en-
dosomal processing to stimulate iNKT cells (5, 20). This was 
done to determine whether APCs from GSL storage disease 
mice had a defect in the capacity to load CD1d with ligands 
in the lysosome.
Sandhoff  , GM1 gangliosidosis, Fabry, or NPC1 spleno-
cytes or BMDCs were pulsed with α-GalCer (Fig. 7, A and 
C; and not depicted) and used to stimulate an iNKT cell hy-
bridoma (DN32-D3), or left unpulsed and used to stimulate 
a control, CD1d-restricted, noninvariant NKT cell hybrid-
oma (TCB11; Fig. 7, E and F). Splenocytes from both Sand-
hoff   and GM1 gangliosidosis mice appeared to be defective in 
presenting  α-GalCer to the DN32 hybridoma compared 
with wild-type controls (Fig. 7 A). Interestingly, the defect in 
ability to present α-GalCer observed with Sandhoff   and GM1 
gangliosidosis splenocytes is not apparent when the APCs 
used were cultured BMDCs (Fig. 7 C).
We also examined the capacity of APCs from GSL stor-
age disease mice to process and present an analogue of α-
  GalCer that is strictly dependent on lysosomal processing, 
galactosyl(α1→2) galactosylceramide (Gal(1→2)GalCer) 
(5, 20). This analogue has a second galactose group linked to 
the primary galactose of α-GalCer and requires processing by 
α-galactosidase (defi  cient in Fabry disease) within the lyso-
some, before recognition in the context of CD1d can occur. 
It has previously been shown that Fabry mice are unable to 
process and present Gal(1→2)GalCer (20).
These experiments were performed using splenocytes 
(Fig. 7 B) or BMDCs (Fig. 7 D) from Sandhoff   and GM1 
gangliosidosis mice, as well as NPC1 mice (unpublished 
data). The response of the DN32 hybridoma to spleno-
cytes or BMDCs from Sandhoff   and GM1 gangliosidosis 
mice pulsed with Gal(1→2)GalCer was reduced compared 
with wild-type controls but was greater than that seen 
with CD1d−/− APCs. Similarly, NPC1 mice had a dra-
matically reduced capacity to present Gal(1→2)GalCer 
(unpublished data).
Table III. Biochemical and cell biological consequences of GSL storage in the thymus of the Sandhoff disease mouse
Control Sandhoff Fold elevation
HPLC analysis of GSLs aGM1a 28.3 ± 2.9 24.8 ± 2.1 0.89
aGM1b 150.3 ± 24 133.7 ± 15.8 0.89
aGA1 121.7 ± 12.6 118.6 ± 12.8 0.97
aGM2 8.3 ± 1.5 b17.9 ± 3.8 2.15
aGA2 34 ± 4.89 b166.9 ± 24.8 4.91
aGM3 5.8 ± 1.05 b2.14 ± 0.75 0.36
Flow cytometry cLysoTracker 100 ± 5.3 b211.3 ± 21.3 2.11
aLevels of GSL species in total thymic extract from 10–12-day-old Sandhoff and control mice (pg/mg protein), as determined by HPLC (reference 41).
bStatistical signifi  cance using the t test (P ≤ 0.05).
cA relative measure of the total acidic late endosomal/lysosomal compartment was made using LysoTracker staining. Flow cytometry was used to analyze LysoTracker-stained 
thymocytes (relative fl  uorescence intensity), gating on the lymphoid population using forward and side scatter parameters.JEM VOL. 203, October 2, 2006  2299
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DISCUSSION
In this study, we investigated a broad range of GSL storage 
disease models, including the NPC1 mouse, which, in con-
trast to the other diseases, has no defect in the catabolic en-
zymes of the lysosome. Specifi  cally, we have studied mouse 
models of GM2 gangliosidosis (Tay-Sachs, LOTS, and 
Sandhoff  ), GM1 gangliosidosis, Fabry, and NPC1. The ma-
jor storage lipids for each of these models are listed in Table I. 
The only common feature shared by these diseases is the 
  accumulation of GSLs in the late endosome/lysosome.
Characterization of iNKT cell frequencies in GSL storage 
disease mice
We have found that iNKT cells are present at reduced per-
centages and frequencies in all mouse models tested, 
irrespective of the specifi  c GSLs stored, and in all organs 
studied (Fig. 1 and Fig. S1). The only exception was the Tay-
Sachs mouse, in which iNKT cells were reduced in the liver 
but normal in the thymus and spleen. This mouse stores only 
modest levels of GM2/GA2 (in contrast with the LOTS and 
Sandhoff   mice) because of a compensatory pathway and does 
not typically develop clinical neurological signs within its 
normal life span (14). It is interesting to note that GSL storage 
is not detectable in thymus or spleen of Tay-Sachs mice, 
whereas there is a fi   vefold elevation of GA2 in the liver 
(Priestman, D., personal communication), implying that GA2 
storage alters the liver microenvironment, aff  ecting iNKT cell 
homeostasis. Disease-dependent variations in organ-specifi  c 
GSL profi  les may explain subtle diff  erences in iNKT cell fre-
quencies in the diff  erent models. Furthermore, the lack of 
GSL storage and normal iNKT cell frequency observed in the 
Tay-Sachs mouse indicates that a threshold level of thymic 
storage may be required to impair iNKT cell development.
Functional characterization of residual iNKT cells
In view of the fact that iNKT cells were not completely ab-
sent, it raised the issue as to whether the residual cells were 
functional. In Sandhoff   and NPC1 mice there was undetect-
able cytokine release in response to α-GalCer injection, rela-
tive to controls (Fig. 2). These results are consistent with 
Figure 7.  Reduced capacity to process and present a lysosome-
dependent analogue of 𝗂-GalCer by GSL storage APCs. Splenocytes 
(A, B, and E) and TNF-α–matured BMDCs (C, D, and F) from control, GM1 
gangliosidosis, Sandhoff, or CD1dKO mice were pulsed for 6 h with either 
α-GalCer (A and C) or Gal(1→2)GalCer (B and D) and used to stimulate 
the DN32-D3 invariant NKT cell hybridoma (A, B, C, and D). Unpulsed 
splenocytes (E) and BMDCs (F) were used to stimulate the CD1d-
  restricted, noninvariant hybridoma TCB11 for 24 h in vitro. Supernatants 
were analyzed using an IL-2 ELISA. Data represent one of two indepen-
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previously published papers (5, 26) demonstrating a reduc-
tion in iNKT cell frequencies in Sandhoff   and NPC1 mice. 
The complete absence of a cytokine response in the storage 
disease mice suggests that if the residual iNKT cells are func-
tional, the levels of cytokines released are below the detec-
tion limit of the assays. Alternatively, they may be defective 
and incapable of responding. In addition, GSL storage disease 
APCs may ineffi   ciently present α-GalCer. To investigate the 
functional capacity of the residual iNKT cells, in vivo killing 
of wild-type α-GalCer–pulsed and C20:2 analogue–pulsed 
(18) targets was assessed in Sandhoff   mice (Fig. 3, B and C). 
As predicted, the specifi  c lysis was reduced (as a result of the 
reduction in iNKT cells). However, there was detectable 
killing (Fig. 3 C) and IFN-γ production (Fig. S2), suggesting 
that the residual iNKT cells are capable of responding to 
  antigen-pulsed wild-type targets. To address the function of 
residual iNKT cells, it would be useful to use intracellular 
  cytokine staining on individual cells. However, in our hands 
this technique was insuffi     ciently sensitive for this purpose 
(unpublished data). Whether residual iNKT cells in Sandhoff   
or GM1 gangliosidosis mice are defective—compared with 
controls—on a per cell basis remains thus unclear.
The role of CD1d expression
In agreement with published studies of the Sandhoff   and pro-
saposin knockout mouse models (5, 27), levels of cell surface 
CD1d were generally unchanged in GSL storage disease mice 
(Fig. 4). Of note, the level of CD1d was reduced on thymo-
cytes and B cells in the NPC1 mouse (Fig. 4). These data 
suggest that the complex pattern of storage lipids in NPC1 
and/or the block in traffi   cking from the late endosome that 
occurs in this disease partially suppresses cell surface CD1d 
expression. However, as all other mouse models tested did 
not exhibit reduced CD1d expression, it is unlikely that the 
decreased CD1d levels in NPC1 mice are entirely responsible 
for the reduction in iNKT cells.
Processing and presentation within the lysosome
Although presentation of peptides by MHC class II molecules 
is unaff  ected in the diff  erent disease mouse models (with the 
exception of NPC1 ; Fig. 5), processing and presentation of 
endogenous or exogenous GSL antigens may be aff  ected by 
GSL storage. To test whether presentation of exogenous 
GSLs was compromised, we used APCs from Sandhoff  , GM1 
gangliosidosis, NPC1, and control mice—loaded with either 
α-GalCer or an analogue, Gal(1→2)GalCer (20)—to stimu-
late a Vα14+ iNKT cell hybridoma (27). In these experi-
ments, CD1d presentation of both α-GalCer (partially 
dependent on lysosomal loading) and Gal(1→2)GalCer 
(strictly dependent on lysosomal processing and loading) (20) 
was impaired in splenocytes from Sandhoff  , GM1 gangliosi-
dosis (Fig. 7, A and B), and NPC1 mice (not depicted). The 
response of the TCB11 control hybridoma was similar be-
tween mouse strains (Fig. 7, E and F).
Experiments performed using Sandhoff  - and GM1 gan-
gliosidosis–cultured BMDCs confi  rmed reduced presentation 
of Gal(1→2)GalCer, as compared with presentation by con-
trol BMDCs (Fig. 7 D). In contrast with splenocytes, BM-
DCs from Sandhoff    and GM1 gangliosidosis mice were 
capable of effi   ciently presenting α-GalCer (Fig. 7, A and C). 
Collectively, these data suggest that the accumulation of GSL 
in the lysosome can impair lysosomal processing and/or load-
ing of CD1d ligands for presentation to iNKT cells. In addi-
tion, the defect in sphingolipid traffi     cking observed in all 
models (28) may contribute to the reduction in exogenous 
ligand presentation. GSL storage by diff  erent GSL storage 
disease model BMDCs was confi  rmed by their elevation in 
LysoTracker staining (unpublished data).
The diff   erence observed between splenocytes and 
  BMDCs in their capacity to present exogenous α-GalCer 
could be explained by several factors. For example, it may 
refl  ect increased glycolipid antigen uptake/processing by an 
enriched population of DCs compared with splenocytes, 
which contains CD1d-positive macrophages and B cells as 
well as DCs. TNF-α–induced maturation of BMDCs could 
further enhance uptake and presentation of glycolipids. Alter-
natively, cultured BMDCs and splenocytes may diff  er with 
  regard to the degree of GSL accumulation within lysosomes.
Interestingly, previously published data (5) did not 
fi  nd any such defect in the capacity to process and present 
Gal(1→2)GalCer by Sandhoff   APCs. It is possible that tech-
nical diff  erences in the experiments—such as the age of the 
mice and, consequently, the degree of GSL accumulation—
may aff  ect the results obtained. A more detailed analysis of 
the eff  ects of age and degree of accumulation on the ability to 
present Gal(1→2)GalCer is currently being undertaken.
Impaired iNKT cell thymic selection in GSL storage mice
Processing and presentation of endogenous iNKT cell select-
ing ligands may also be aff  ected by GSL storage. The reduc-
tion of iNKT cells in GSL storage mice might therefore be 
caused by a reduced capacity to positively select iNKT cells 
during thymic development. A reduction of iNKT cells at 
all developmental stages was observed in the thymus of young 
adult Sandhoff   and GM1 gangliosidosis mice (Fig. 6). Inter-
estingly, we found a signifi  cant reduction in the frequency of 
iNKT cells in Sandhoff   mice at postnatal day 12 (unpublished 
data), when appreciable levels of GSL storage are already de-
tected (Table III), suggesting that accumulation of GSLs in 
thymocytes may lead to a decreased capacity to positively 
  select iNKT cells.
Loss of iNKT cells in mouse models characterized by 
  lysosomal GSL accumulation has previously been described. 
One report (20) proposed that the loss of iNKT cells in Fabry 
mice was indicative of a requirement for α-galactosidase 
(the enzyme defi  cient in Fabry disease) for the generation 
of glycolipid ligands recognized by iNKT cells. Another 
group observed a reduction in iNKT cells in Sandhoff   mice 
and concluded that there was an essential requirement for 
β-  hexosaminidase A/B (the enzymes defi  cient in Sandhoff   
mice) to generate the endogenous lipid necessary for selec-
tion of iNKT cells (5). Of the candidate substrates tested, JEM VOL. 203, October 2, 2006  2301
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iGb3 was proposed to be the selecting ligand based upon its 
activity in vitro. Likewise, recent studies with prosaposin-
  defi  cient mice revealed a similar reduction in iNKT cell fre-
quencies, suggesting an essential role for saposins in the 
loading of CD1d (27). Interestingly, a paper was recently 
published supporting our observations of a reduction of 
iNKT cells in NPC1 mice (26).
Alternative hypothesis and potential mechanisms
Our data obtained from a range of diff  erent GSL storage 
models, including GM1 gangliosidosis and NPC1, support 
the hypothesis that lysosomal lipid storage has an indepen-
dent, nonspecifi  c negative eff  ect on iNKT cell selection. In 
NPC1 mice, reduced iNKT cell frequencies may be caused 
by a combined eff  ect of GSL storage, impaired GSL traffi   ck-
ing, and decreased CD1d expression (26). This hypothesis 
could also explain the fi  nding that iNKT cells are reduced in 
Fabry mice, where the defi  ciency in α-galactosidase A should 
lead to lysosomal accumulation of iGb3, the recently identi-
fi  ed candidate endogenous ligand for iNKT cells.
We propose an alternative model to explain iNKT cell 
loss in the disparate mouse models investigated in this study 
and others (5, 20, 26, 27). The storage of any GSL above a 
certain threshold in the late endosome/lysosome, irrespective 
of its structure, could impair iNKT cell development. It is the 
storage per se rather than a specifi  c enzyme defect that results 
in iNKT cell defi  ciency. This model is also consistent with 
the iNKT cell reduction observed in the saposin-null mice 
because GSLs accumulate as a result of the saposin defi  ciency. 
In addition, lack of lipid solubilization (29) mediated by sa-
posins may further impair the loading of CD1d with endoge-
nous iNKT cell selecting ligands. Therefore, saposin-defi  cient 
mice suff  er from the combined eff  ects of GSL storage and 
  reduced GSL loading. This may also explain why residual 
iNKT cells are detectable in the Fabry, Sandhoff  , GM1 gan-
gliosidosis, and NPC1 mice (GSL storage), whereas they are 
undetectable in the saposin-defi  cient animals (GSL storage 
and loading defect).
There are several potential mechanisms to envision for 
how GSL storage aff  ects CD1d loading. The fi  rst would be 
that endogenous GSLs normally presented by CD1d become 
trapped within the storage bodies in the diseased cells and 
consequently are not loaded onto CD1d. A second hypothe-
sis would be that the high levels of storage GSLs outnumber 
natural ligands within the late endosome/lysosome and, 
therefore, out-compete the endogenous lipids for binding to 
CD1d. Both of these models are consistent with a threshold 
level of storage being required to disrupt iNKT cell develop-
ment. This is supported by the intermediate iNKT cell loss 
exhibited by the Tay-Sachs mouse (Fig. 1) that has subpatho-
logical levels of GSL storage (Table I). Alternatively, GSL 
storage may indirectly infl  uence iNKT cell selection. The 
defect in sphingolipid traffi   cking (27) observed in all GSL 
storage disease models may disrupt the cellular distribution of 
the selecting ligands, reducing their presentation by CD1d 
and iNKT cell selection. The proposed mechanisms by which 
GSL storage disrupts iNKT cell selection are not mutually 
exclusive and, therefore, we cannot rule out that this also 
plays a role.
It will be interesting to determine whether comparable 
iNKT cell defi  ciencies occur in patients with glycosphingo-
lipidoses. Although these studies are currently in progress, a 
recent report has described that Gaucher patients (who pos-
sess a defect in the lysosomal enzyme glucocerebrosidase) 
treated with enzyme replacement therapy showed a modest 
increase in the proportion of Vα24+ cells in the peripheral 
CD4+ and CD8+ T cell pool (30). Should the fi  ndings of our 
study translate to the human disorders, iNKT cell defi  ciency 
may be a contributing factor to the clinical heterogeneity 
characteristic of these diseases. It is possible that this may have 
consequences for host immune responses by reducing the 
  effi   cacy of presentation of bacterial or endogenous GSLs.
In summary, storage of multiple GSLs with disparate 
structures, resulting from unique etiologies, causes defective 
iNKT cell selection. Our data suggest general mechanisms by 
which lysosomal storage of GSLs, irrespective of the underly-
ing gene defect, can disrupt the presentation of endogenous 
ligands by CD1d.
MATERIALS AND METHODS
Animals. The following mouse models of GSL storage (C57BL/6 back-
ground) were maintained and genotyped according to published methods: 
Tay-Sachs hexa−/− (31); LOTS hexa−/− (32); Sandhoff   hexb−/− (33); Fabry 
α-galA−/− (34); and GM1 gangliosidosis bgal−/− (35). Each mouse strain had 
been backcrossed at least eight times before use. LOTS mice are female 
Tay-Sachs mice that have been repeatedly bred before 6 mo of age (32). 
Tay-Sachs (nonbred) mice are asymptomatic because of the presence of a 
bypass pathway (the combined eff  ects of sialidase and hexosaminidase B). 
Pregnancy induces down-regulation of components of the bypass pathway, 
causing higher levels of storage relative to the Tay-Sachs mouse and clinical 
presentation in 100% of LOTS mice. NPC1 mice (13) are on a BALB/c 
background. Also used were mice lacking the Jα18 TCR gene segment (36), 
which were devoid of Vα14 iNKT cells while having other lymphoid cell 
lineages intact (iNKT−/− mice), and CD1d knockout mice (CD1d−/−) (37), 
which were also devoid of Vα14 iNKT cells. Heterozygote littermates and 
age-matched C57BL/6 or NPC1+/+ mice, as appropriate, were used as con-
trols. All mice were maintained in the Biological Services Unit, Department 
of Biochemistry, University of Oxford and used according to established 
University of Oxford institutional guidelines under the authority of a UK 
Home Offi   ce project license.
Cell preparations. Intrahepatic mononuclear cells were separated from 
mouse livers according to the following protocol: livers were cut into small 
pieces using a scalpel, passed through a 100-mm metal mesh fi  lter, washed 
twice with PBS, layered over Ficoll-Hypaque gradients, and centrifuged at 
2,000 rpm at room temperature for 20 min. An analogous procedure was 
used to separate splenic and thymic mononuclear cells. Before staining for 
FACS, both intrahepatic and splenic mononuclear cells were incubated for 
10 min at room temperature with 20 μg of unconjugated anti-FcR antibody 
(BD Biosciences). For all FACS staining experiments, three to fi  ve animals 
per group were used.
Flow cytometry. Cell suspensions were stained according to published 
methods (38). In brief, 106 cells in 50 μl FACS buff  er (PBS containing 1% 
bovine serum albumin and 0.02 M sodium azide) were incubated on ice for 
30 min with monoclonal antibodies (all from BD Biosciences) or α-GalCer/
CD1d tetramer (39), followed by two washes in FACS buff  er. The anti-
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(CD1.1, Ly-38), FITC-conjugated rat anti–mouse CD19 (1D3), hamster 
anti–mouse CD11c (HL3), and CD68. Allophycocyanin-conjugated strep-
tavidin (Phykolink) and RPE-conjugated Extraavidin (Sigma-Aldrich) were 
used for the generation of CD1d tetramers. CD1d tetramers were generated 
as previously described (39). Propidium iodide was used to gate out dead 
cells. Quantitation of binding sites was performed using fl  uorescent micro-
bead standards according to published methods (38). To analyze the matura-
tion phenotype of iNKT thymocytes, cells were stained with CD1d/α-GalCer 
tetramer–PE, NK1.1-PerCP, pan Vβ–FITC, and CD44-allophycocyanin 
(BD Biosciences). To analyze lysosomes, 106 cells from 10–12-d-old Sand-
hoff   and control thymi were stained in 200 μl 200 nM LysoTracker-Green 
(Invitrogen) for 10 min at room temperature. After washing, the cells were 
analyzed by fl  ow cytometry gating on thymocytes by forward and side scat-
ter. Percentages of APCs were analyzed by staining cells from diff  erent tis-
sues with CD11c and CD68 antibodies.
Cytokine assays. Animals were injected i.v. with 1 μg α-GalCer (dissolved 
in a vehicle solution of 0.5% Tween 20/PBS) or vehicle diluted in PBS. 
Blood samples were collected at the time points indicated in the fi  gures, and 
serum levels of IL-4 and IFN-γ were determined using cytokine-specifi  c 
capture ELISAs. Antibodies used for ELISAs were obtained from eBiosci-
ence and Pierce Chemical Co.
In vivo cytotoxicity assay. Target splenocytes were pulsed with 5, 0.5, 
and 0.05 μg/ml α-GalCer or C20:2 analogue for 2 h at 37°C and labeled 
with diff  erent concentrations (1.65, 0.3, and 0.07 nM) of CFSE (Invitrogen), 
as previously described (17). A control vehicle-pulsed population was labeled 
with 10 μM chloromethyl-benzoyl-aminotetramethyl-rhodamine (CMTMR; 
Invitrogen). An equal mixture of the four populations of splenocytes was in-
jected i.v. at 107 cells/mouse into Sandhoff   homozygote mice, age-matched 
littermate controls, and iNKT−/− mice (n = 3–5 mice/group). 48 h after in-
jection, blood samples were examined for the presence of fl  uorescent cells by 
fl  ow cytometry (FACSCalibur; BD Biosciences). Data are expressed as per-
cent survival of α-GalCer– or analogue-pulsed splenocytes compared with 
unpulsed controls. Mean percent specifi  c lysis (±SEM) of α-GalCer–pulsed 
splenocytes compared with unpulsed controls was calculated by the follow-
ing formula: 100 − ([pulsed/unpulsed] × 100).
Monitoring MHC class II–restricted T cell responses. Sandhoff   ho-
mozygotes (6 and 10 wk of age) or other GSL storage mice and age-matched 
controls were immunized s.c. with 100 μg chicken OVA protein (Sigma-
Aldrich) in CFA (Sigma-Aldrich). 11 d later, the mice were injected i.v. 
with 2 × 106 PFU/mouse UV-inactivated recombinant vaccinia virus en-
coding full-length chicken OVA. After 7 d, immune responses were assessed 
by performing ELISPOT using a mouse IFN-γ ELISPOT kit (Mabtech) and 
10 μM of two diff  erent I-Ab–restricted OVA peptides (synthesized in house), 
OVA265-280 (T E  W  T  S  S  N  V  M  E  E  R  K  I  K  V  ) and OVA323-339 (I S  Q  A  V  H  A  A  H  A  E-
I  N  E  A  G  R  ), according to the manufacturer’s protocol.
Analysis of GSL storage. Thymi from 10–12-d-old Sandhoff   mice and 
controls were homogenized in 0.5 ml distilled water, and GSLs were ex-
tracted using the Svernnerholm method (40). The equivalent of 200 μg 
protein was treated with ceramide glycanase (Calbiochem-Novabiochem). 
Released glycans were labeled with anthranillic acid (Sigma-Aldrich) and 
analyzed by HPLC as described previously (41).
Processing and presentation of 𝗂-GalCer and analogues by GSL 
storage disease APCs. APCs used were either BMDCs, cultured for 7 d 
in the presence of 20 ng/ml GM-CSF/IL-4 (PeproTech) and matured from 
day 6 of culture with 10 ng/ml TNF-α (PeproTech) or splenocytes. APCs 
were pulsed with α-GalCer, Gal(1→2)GalCer, or vehicle for 6 h, washed, 
and 5 × 105 splenocytes or 5 × 104 BMDCs were added to 96-well fl  atbot-
tom plates. The DN32-D3 iNKT cell hybridoma or the control, CD1d-
  restricted, non–iNKT cell hybridoma (TCB11) from A. Bendelac (University 
of Chicago, Chicago, IL) and S. Porcelli (Albert Einstein School of Medicine, 
New York, NY) were added (5 × 104) to each well. Cells were cultured 
for 18–24 h at 37°C, and the supernatant was analyzed for the presence of 
IL-2 by ELISA (antibodies used were anti–mouse IL-2 JES6-1A12 and 
  biotinylated JES6-5H4; eBioscience).
Online supplemental material. In Fig. S1, lymphocyte preparations 
from the spleen and thymus were generated, and cells were counted. Lym-
phocytes were stained for iNKT cells as described in Flow cytometry, and 
samples were analyzed. The cell number and frequency of iNKT cells as a 
percentage of total lymphocytes were then used to calculate the number of 
tissue iNKT cells.
In Fig. S2, the ability of iNKT cells from storage disorder mice to 
mount a cytokine response was assayed by performing an overnight IFN-γ 
ELISPOT using T cell–enriched splenocytes incubated with BMDCs loaded 
with α-GalCer. Splenocyte cell preparations were enriched for T cells by in-
cubating for 1 h at 37°C, adhering out the macrophages. BMDCs derived 
from wild-type mice were pulsed for 3 h with 5 μg/ml α-GalCer. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20060921/DC1.
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